Figure 5

Analysis of the relationship between calcium channel phenotype and response to immunotherapy. (A) Analysis of TIDE score difference between the two subtypes (Wilcoxon test, TCGA-LIHC, n = 370). (B) Analysis of alterations in the immune cell abundance between two subtypes. The x-axis represents the immune cell type, and y-axis represents the immune score (CIBERSORT scores) in varying subtypes where distinct colors denote distinct subtypes. C1 (red) and C2 (blue), TCGA-LIHC. (C) Analysis of the differences in eight common ICPs between two subtypes (Wilcoxon test, TCGA-LIHC, n = 370). (D) Correlation between FSTL3, TMEM51, PKM, SERPINC1 expression and TIDE score as evaluated based on TCGA-LIHC (Spearman method, n = 370). (E) Expression difference analyses of FSTL3, TMEM51, PKM, and SERPINC1 based on TCGA-LIHC paired samples (Wilcoxon test, n = 50). (F) Human FSTL3 and PKM expression levels in different tumor types from TCGA database. Wilcoxon test was conducted. (G) FSTL3 expression differential analysis between tumor and normal tissues based on GSE10279 (left, n = 257), and GSE36376 (right, n = 433). Wilcoxon test was conducted. (H) Different IHC staining intensity of FSTL3 in HCC patients. (I) Statistical analysis of FSTL3 contents (H-SCORE) in normal and tumor tissues (Wilcoxon test, n = 40). (J) Expression difference analyses of FSTL3 between C1 and C2 (Wilcoxon test, TCHA-LIHC, n = 50). (K–M) Correlation between FSTL3 and MSI (K), TMB (L), as well as PDCD1 (M), respectively (Spearman method, TCGA-LIHC, n = 370). (N) Box plot depicting different FSTL3 expressions between responder and non-responder following anti-PD-1 treatment in 40 HCC patients. (O) The high/low FSTL3 expression groups were divided depending on median of IHC scores of 40 HCC patients’ specimens. Bar plot depicting different response rates between elevated- and reduced-FSTL3 expression cohorts among 40 HCC patients. In the low FSTL3 expression groups, 14 patients were responders to anti-PD-1 therapy, and 6 patients were non-responders. There were 8 patients were responders to anti-PD-1 therapy, and 12 patients were non-responders in high FSTL3 expression groups. (**** P < 0.0001, *** P < 0.001, ** P < 0.01, * P < 0.05, ns not significant).